Annals of Oncology
8. Martinson HA, Jindal S, Durand-Rougely C, et al. Wound healing-like
immune program facilitates postpartum mammary gland involution
and tumor progression. Int J Cancer. 2015;136(8):1803-1813.
9. Andersson TM, Johansson ALV, Hsieh CC, et al. Increasing incidence
of pregnancy-associated breast cancer in Sweden. Obstet Gynecol.
2009;114(3):568-572.
10. Eibye S, Kjaer SK, Mellemkjaer L. Incidence of pregnancy-associated
cancer in Denmark, 1977-2006. Obstet Gynecol. 2013;122(3):608-617.
11. Lee YY, Roberts CL, Dobbins T, et al. Incidence and outcomes of
pregnancy-associated cancer in Australia, 1994-2008: a population-
based linkage study. BJOG. 2012;119(13):1572-1582.
12. Parazzini F, Franchi M, Tavani A, et al. Frequency of pregnancy related
cancer: a population based linkage study in Lombardy, Italy. Int J
Gynecol Cancer. 2017;27(3):613-619.
13. Azim HA Jr, Brohee S, Peccatori FA, et al. Biology of breast cancer
during pregnancy using genomic profiling. Endocr Relat Cancer.
2014;21(4):545-554.
14. Piccart M, van ‛t Veer LJ, Poncet C, et al. 70-gene signature as an aid
for treatment decisions in early breast cancer: updated results of the
phase 3 randomised MINDACT trial with an exploratory analysis by
age. Lancet Oncol. 2021;22(4):476-488.
15. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy
guided by a 21-gene expression assay in breast cancer. N Engl J Med.
2018;379(2):111-121.
16. Villarreal-Garza C, Ferrigno AS, De la Garza-Ramos C, et al. Clinical
utility of genomic signatures in young breast cancer patients: a sys-
tematic review. NPJ Breast Cancer. 2020;6:46.
17. Azim HA Jr, Michiels S, Bedard PL, et al. Elucidating prognosis and
biology of breast cancer arising in young women using gene
expression profiling. Clin Cancer Res. 2012;18(5):1341-1351.
18. Azim HA Jr, Partridge AH. Biology of breast cancer in young women.
Breast Cancer Res. 2014;16(4):427.
19. Sood R, Rositch AF, Shakoor D, et al. Ultrasound for breast cancer
detection globally: a systematic review and meta-analysis. J Glob
Oncol. 2019;5:1-17.
20. Taylor D, Lazberger J, Ives A, et al. Reducing delay in the diagnosis of
pregnancy-associated breast cancer: how imaging can help us. J Med
Imaging Radiat Oncol. 2011;55(1):33-42.
21. Alvarez S, Anorbe E, Alcorta P, et al. Role of sonography in the
diagnosis of axillary lymph node metastases in breast cancer: a sys-
tematic review. AJR Am J Roentgenol. 2006;186(5):1342-1348.
22. Alkuwari E, Auger M. Accuracy of fine-needle aspiration cytology of
axillary lymph nodes in breast cancer patients: a study of 115 cases
with cytologic-histologic correlation. Cancer. 2008;114(2):89-93.
23. Ray JG, Vermeulen MJ, Bharatha A, et al. Association between MRI
exposure during pregnancy and fetal and childhood outcomes. JAMA.
2016;316(9):952-961.
24. Nissan N, Bauer E, Moss Massasa EE, et al. Breast MRI during preg-
nancy and lactation: clinical challenges and technical advances. In-
sights Imaging. 2022;13(1):71.
25. Amornsiripanitch N, Bickelhaupt S, Shin HJ, et al. Diffusion-weighted
MRI for unenhanced breast cancer screening. Radiology. 2019;293(3):
504-520.
26. Han SN, Amant F, Michielsen K, et al. Feasibility of whole-body
diffusion-weighted MRI for detection of primary tumour, nodal and
distant metastases in women with cancer during pregnancy: a pilot
study. Eur Radiol. 2018;28(5):1862-1874.
27. Jha P, Poder L, Glanc P, et al. Imaging cancer in pregnancy. Radio-
graphics. 2022;42(5):1494-1513.
28. Vandecaveye V, Amant F, Lecouvet F, et al. Imaging modalities in
pregnant cancer patients. Int J Gynecol Cancer. 2021;31(3):423-431.
29. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2019;30(10):1674.
30. Pesapane F, Downey K, Rotili A, et al. Imaging diagnosis of metastatic
breast cancer. Insights Imaging. 2020;11(1):79.
31. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from
cancers of the gastrointestinal tract by using noninvasive imaging
16 https://doi.org/10.1016/j.annonc.2023.08.001
S. Loibl et al.
methods (US, CT, MR imaging, PET): a meta-analysis. Radiology.
2002;224(3):748-756.
32. Lind K, Borhani-Khomani K, Okholm M, et al. Routine X-ray of the
chest is not justified in staging of patients with primary breast cancer.
Dan Med J. 2022;69(11):A06220380.
33. Woitek R, Prayer D, Hojreh A, et al. Radiological staging in pregnant
patients with cancer. ESMO Open. 2016;1(1):e000017.
34. Shen G, Deng H, Hu S, et al. Comparison of choline-PET/CT, MRI,
SPECT, and bone scintigraphy in the diagnosis of bone metastases in
patients with prostate cancer: a meta-analysis. Skeletal Radiol.
2014;43(11):1503-1513.
35. Wu LM, Hu J, Gu HY, et al. Can diffusion-weighted magnetic reso-
nance imaging (DW-MRI) alone be used as a reliable sequence for the
preoperative detection and characterisation of hepatic metastases? A
meta-analysis. Eur J Cancer. 2013;49(3):572-584.
36. Peccatori FA, Codacci-Pisanelli G, Del Grande M, et al. Whole body
MRI for systemic staging of breast cancer in pregnant women. Breast.
2017;35:177-181.
37. Petralia G, Padhani AR, Pricolo P, et al. Whole-body magnetic reso-
nance imaging (WB-MRI) in oncology: recommendations and key
uses. Radiol Med. 2019;124(3):218-233.
38. Zugni F, Ruju F, Pricolo P, et al. The added value of whole-body
magnetic resonance imaging in the management of patients with
advanced breast cancer. PLoS One. 2018;13(10):e0205251.
39. Stolzmann P, Veit-Haibach P, Chuck N, et al. Detection rate, location,
and size of pulmonary nodules in trimodality PET/CT-MR: comparison
of low-dose CT and Dixon-based MR imaging. Invest Radiol.
2013;48(5):241-246.
40. American College of Obstetricians, Gynecologists’ Committee on
Obstetric Practice. Committee Opinion No. 656 Summary: Guidelines
for diagnostic imaging during pregnancy and lactation. Obstet Gyne-
col. 2016;127(2):418.
41. Amant F, von Minckwitz G, Han SN, et al. Prognosis of women with
primary breast cancer diagnosed during pregnancy: results from an
international collaborative study. J Clin Oncol. 2013;31(20):2532-2539.
42. Azim HA Jr, Botteri E, Renne G, et al. The biological features and
prognosis of breast cancer diagnosed during pregnancy: a case-
control study. Acta Oncol. 2012;51(5):653-661.
43. Litton JK, Warneke CL, Hahn KM, et al. Case control study of women
treated with chemotherapy for breast cancer during pregnancy as
compared with nonpregnant patients with breast cancer. Oncologist.
2013;18(4):369-376.
44. Azim HA Jr, Peccatori FA, Brohee S, et al. RANK-ligand (RANKL)
expression in young breast cancer patients and during pregnancy.
Breast Cancer Res. 2015;17:24.
45. Nguyen B, Venet D, Azim HA Jr, et al. Breast cancer diagnosed during
pregnancy is associated with enrichment of non-silent mutations,
mismatch repair deficiency signature and mucin mutations. NPJ
Breast Cancer. 2018;4:23.
46. Johansson ALV, Fredriksson I, Mellemkjaer L, et al. Cancer survival in
women diagnosed with pregnancy-associated cancer: an overview
using nationwide registry data in Sweden 1970-2018. Eur J Cancer.
2021;155:106-115.
47. Shao C, Yu Z, Xiao J, et al. Prognosis of pregnancy-associated breast
cancer: a meta-analysis. BMC Cancer. 2020;20(1):746.
48. Puchar A, Despierres M, Boudy AS, et al. Prognosis of triple-negative
breast cancer associated with pregnancy: a propensity score-matched
analysis from the French CALG (Cancer Associe a la Grossesse)
network. Breast. 2022;61:168-174.
49. Amant F, Nekljudova V, Maggen C, et al. Outcome of breast cancer
patients treated with chemotherapy during pregnancy compared
with non-pregnant controls. Eur J Cancer. 2022;170:54-63.
50. Osborne CM, Hardisty E, Devers P, et al. Discordant noninvasive
prenatal testing results in a patient subsequently diagnosed with
metastatic disease. Prenat Diagn. 2013;33(6):609-611.
51. Amant F, Verheecke M, Wlodarska I, et al. Presymptomatic identifi-
cation of cancers in pregnant women during noninvasive prenatal
testing. JAMA Oncol. 2015;1(6):814-819.
Volume xxx - Issue xxx - 2023